Image-Based Investigation: Biorelevant Solubility of α and γ Indomethacin

被引:17
作者
Stukelj, Jernej [1 ,2 ]
Svanback, Sami [1 ,2 ]
Kristl, Julijana [3 ]
Strachan, Clare J. [1 ]
Yliruusi, Jouko [1 ]
机构
[1] Univ Helsinki, Div Pharmaceut Chem & Technol, Viikinkaari 5E, Helsinki 00790, Finland
[2] Solubil Co, Viikinkaari 6, Helsinki 00790, Finland
[3] Univ Ljubljana, Fac Pharm, Askerceva 7, Ljubljana 1000, Slovenia
基金
芬兰科学院;
关键词
BIOPHARMACEUTIC-DRUG-CLASSIFICATION; DISSOLUTION MEDIA; THEORETICAL-BASIS; SOLUBLE DRUGS; POLYMORPHS; IMPACT;
D O I
10.1021/acs.analchem.8b05290
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Solubility is a physicochemical property highly dependent on the solid-state form of a compound. Thus, alteration of a compound's solid-state form can be undertaken to enhance the solubility of poorly soluble drug compounds. In the Biopharmaceutics Classification System (BCS), drugs are classified on the basis of their aqueous solubility and permeability. However, aqueous solubility does not always correlate best with in vivo solubility and consequently bioavailability. Therefore, the use of biorelevant media is a more suitable approach for mimicking in vivo conditions. Here, assessed with a novel image-based single-particle analysis (SPA) method, we report a constant ratio of solubility increase of 3.3 +/- 0.5 between the alpha and gamma solidstate forms of indomethacin in biorelevant media. The ratio was independent of pH, ionic strength, and surfactant concentration, which all change as the drug passes through the gastrointestinal tract. On the basis of the solubility ratio, a free energy difference between the two polymorphic forms of 2.9 kJ/mol was estimated. Lastly, the use of the SPA approach to assess solubility has proven to be simple, fast, and both solvent- and sample-sparing, making it an attractive tool for drug development.
引用
收藏
页码:3997 / 4003
页数:7
相关论文
共 32 条
[1]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[2]  
Augustijns P., 2007, Biotechnology: Pharmaceutical Aspects, VVI, P53
[3]   Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound [J].
Baka, Edit ;
Comer, John E. A. ;
Takacs-Novak, Krisztina .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 46 (02) :335-341
[4]   Solubility: it's not just for physical chemists [J].
Bhattachar, Shobha N. ;
Deschenes, Laura A. ;
Wesley, James A. .
DRUG DISCOVERY TODAY, 2006, 11 (21-22) :1012-1018
[5]  
BORKA L, 1974, ACTA PHARM SUEC, V11, P295
[6]   Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development [J].
Chemburkar, SR ;
Bauer, J ;
Deming, K ;
Spiwek, H ;
Patel, K ;
Morris, J ;
Henry, R ;
Spanton, S ;
Dziki, W ;
Porter, W ;
Quick, J ;
Bauer, P ;
Donaubauer, J ;
Narayanan, BA ;
Soldani, M ;
Riley, D ;
McFarland, K .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2000, 4 (05) :413-417
[7]   Dissolution Rate and Apparent Solubility of Poorly Soluble Drugs in Biorelevant Dissolution Media [J].
Fagerberg, Jonas H. ;
Tsinman, Oksana ;
Sun, Na ;
Tsinman, Konstantin ;
Avdeef, Alex ;
Bergstrom, Christel A. S. .
MOLECULAR PHARMACEUTICS, 2010, 7 (05) :1419-1430
[8]  
Florence A.T., 2006, PHYSICOCHEMICAL PRIN, P139
[9]   Drugs as materials:: Valuing physical form in drug discovery [J].
Gardner, CR ;
Walsh, CT ;
Almarsson, Ö .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (11) :926-934
[10]   What is the true solubility advantage for amorphous pharmaceuticals? [J].
Hancock, BC ;
Parks, M .
PHARMACEUTICAL RESEARCH, 2000, 17 (04) :397-404